FDA Adverse Event Injury Summary report: N

SENHANCE

MDR report key: 17774375 · Received September 19, 2023

Report

Report Number
3007593944-2023-00003
Event Type
Injury
Date Received
September 19, 2023
Date of Event
September 27, 2020
Report Date
October 12, 2023
Manufacturer
ASENSUS SURGICAL, INC.
Product Code
NAY
PMA / PMN Number
K171120
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
LH
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

BASED ON THE COMPLAINT DETAILS (B)(4) THE PATIENT EXPERIENCED COLOANAL ANASTOMOTIC LEAKAGE, WAS TREATED WITH ANTIBIOTICS (METRONIDAZOLE 500MG 3X DAILY, CEFUROXIME 1G 3X DAILY), AND THE SYMPTOMS DISAPPEARED. THIS EVENT DID NOT OCCUR WITHIN THE UNITED STATES. THIS EVENT OCCURRED AT KLAIPEDA UNIVERSITY HOSPITAL IN LITHUANIA. THE EVENT OCCURRED ON (B)(6) 2020 (WAS RESOLVED ON (B)(6) 2020), AND ASENSUS SURGICAL WAS MADE AWARE ON 09-AUGUST-2023. ACCORDING TO THE INVESTIGATION, FURTHER RESPONSES FROM SURGEON INTERVIEWS INDICATED THAT THE ANASTOMOTIC LEAKAGE EVENT WAS NOT RELATED TO THE SENHANCE SURGICAL SYSTEM, BUT RATHER CONSIDERED TO BE A NORMAL SURGICAL COMPLICATION UNRELATED TO THE ROBOT. FURTHERMORE, NO MALFUNCTION OF THE SENHANCE SYSTEM WAS REPORTED AND NO FAILURES WERE IDENTIFIED. THE RISK POSED BY THIS EVENT WAS EVALUATED THROUGH A HEALTH HAZARD EVALUATION (HHE-001-00026) AND A CORRECTIVE ACTION PREVENTATIVE ACTION PLAN (CAPA-000048) HAS BEEN OPENED TO MANAGE THE UNSUITABLE TIMELINESS OF THE RECEIPT AND MANAGEMENT OF THIS REPORTED EVENT. THEREFORE, ASENSUS SURGICAL IS REPORTING THIS FOLLOWUP FOR COMPLETENESS TO THE INITIAL MDR REPORT SUBMITTED ON 19-SEPTEMBER-2023.

Description of Event or Problem · 0

THE COMPLAINANT, (B)(6) REPORTED THAT ON DAY 7, AFTER TME FOR RECTAL CANCER PATIENT COMPLAINED OF SUDDEN PURULENT DISCHARGE FROM THE ANUS AND ELEVATED BLOOD TEMPERATURE, SOME WEAKNESS. THIS ADVERSE EVENT WAS AN ANASTOMOTIC LEAKAGE. A DIGITAL EXAMINATION REVEALED A DEFECT OF (1 CM) IN THE POSTERIOR WALL OF COLO-ANAL ANASTOMOSIS. ANTIBIOTICS WERE ADMINISTERED (METRONIDAZOLE-500 MG 3X DAILY AND CEFUROXIME-1 G 3X DAILY) AND SYMPTOMS DISSAPEARED FOR A RESOLUTION DATE OF (B)(6) 2020. THIS EVENT DID NOT OCCUR WITHIN THE UNITED STATES. THE EVENT OCCURRED IN (B)(6). IT WAS REPORTED THAT THE CAUSALITY TO THE SENHANCE SURGICAL SYSTEM WAS POSSIBLE. THE EVENT OCCURRED ON (B)(6) 2020, AND ASENSUS SURGICAL WAS INTERNALLY MADE AWARE ON 09-AUGUST-2023..

Description of Event or Problem · 0

THE COMPLAINANT, (B)(6), REPORTED THAT ON DAY 7, AFTER TME FOR RECTAL CANCER PATIENT COMPLAINED OF SUDDEN PURULENT DISCHARGE FROM THE ANUS AND ELEVATED BLOOD TEMPERATURE, SOME WEAKNESS. THIS ADVERSE EVENT WAS AN ANASTOMOTIC LEAKAGE. A DIGITAL EXAMINATION REVEALED A DEFECT OF (1 CM) IN THE POSTERIOR WALL OF COLO-ANAL ANASTOMOSIS. ANTIBIOTICS WERE ADMINISTERED (METRONIDAZOLE-500 MG 3X DAILY AND CEFUROXIME-1 G 3X DAILY) AND SYMPTOMS DISAPPEARED FOR A RESOLUTION DATE OF (B)(6) 2020. THIS EVENT DID NOT OCCUR WITHIN THE UNITED STATES. THE EVENT OCCURRED IN (B)(6) HOSPITAL IN LITHUANIA. IT WAS REPORTED THAT THE CAUSALITY TO THE SENHANCE SURGICAL SYSTEM WAS POSSIBLE. THE EVENT OCCURRED ON (B)(6) 2020, AND ASENSUS SURGICAL WAS INTERNALLY MADE AWARE ON 09-AUGUST-2023.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1986441 SENHANCE SENHANCE SURGICAL SYSTEM NAY ASENSUS SURGICAL, INC.

Patients

Seq Age Sex Outcome Treatment
1 Unknown Required Intervention